Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer.

MLA

Ravi K Anchoori, et al. “Preclinical Studies of RA475, a Guanidine-Substituted Spirocyclic Candidate RPN13/ADRM1 Inhibitor for Treatment of Ovarian Cancer.” PLoS ONE, vol. 19, no. 7, Jan. 2024, p. e0305710. EBSCOhost, https://doi.org/10.1371/journal.pone.0305710.

APA

Ravi K Anchoori, Ssu-Hsueh Tseng, Hua-Ling Tsai, Vikrant Palande, Michelle A Rudek, & Richard B S Roden. (2024). Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer. PLoS ONE, 19(7), e0305710. https://doi.org/10.1371/journal.pone.0305710

Chicago

Ravi K Anchoori, Ssu-Hsueh Tseng, Hua-Ling Tsai, Vikrant Palande, Michelle A Rudek, and Richard B S Roden. 2024. “Preclinical Studies of RA475, a Guanidine-Substituted Spirocyclic Candidate RPN13/ADRM1 Inhibitor for Treatment of Ovarian Cancer.” PLoS ONE 19 (7): e0305710. doi:10.1371/journal.pone.0305710.